Cara Therapeutics: CHMP Recommends Approval Of Kapruvia

Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. (CARA) announced that the European Medicines Agency's CHMP has recommended approval of Kapruvia for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in hemodialysis patients. The companies noted that, if approved, Kapruvia will be the first therapy available in Europe for the treatment of chronic kidney disease-associated pruritus in hemodialysis patients.

The positive CHMP opinion is based on pivotal clinical data from two phase-III trials, KALM-1 and KALM-2, and supportive data from an additional 32 clinical studies. European Commission decision for marketing authorization is anticipated in the second quarter of 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Integrated energy company Chevron reported Friday that profit for the fourth quarter increased 25 percent from last year, reflecting 17 percent revenue growth amid higher realizations and higher margins on refined product sales. Adjusted earnings per share missed analysts' estimates, while quarterly revenues topped it. Reno, Nevada-based ZLINE Kitchen and Bath has expanded its recall of gas ranges citing serious risk of injury or death from carbon monoxide poisoning, the U.S. Consumer Product Safety Commission announced. The recall now includes about 30,000 units of ZLINE gas ranges, including about 28,000 units... The Food and Drug Administration's independent advisory committee unanimously recommended replacing the current original COVID vaccines used in the U.S. for primary shots with new bivalent omicron shots authorized as boosters, reports said. The committee also considered the proposal for annual COVID vaccination, however, didn't vote on it.
Follow RTT